Drug Discovery App CS WP

  1. How EPR Unlocks Missing Dynamics In Pharma And Structural Biology Workflow 10/1/2026

    Uncover how EPR spectroscopy fills the conformational gap by capturing dynamic protein motions, refining Cryo-EM models, and revealing hidden structural ensembles for drug discovery.

  2. Beyond The Bioreactor Scaling CGT Ancillary Materials With The EntoEngineā„¢ 9/26/2026

    Growing demand for cell and gene therapies is increasing pressure on cytokine production. Explore interleukin manufacturing, quality, consistency, safety, scalability, and supply reliability.

  3. From Sequence To Scale In Seven Months 9/26/2026

    Accelerate recombinant protein development from sequence to scale while maintaining stable expression, manufacturing efficiency, and critical quality attributes.

  4. Manufacturing Glycosylated Erythropoietin Without š¯›¼1,3-Fucosylation 9/26/2026

    See how expression hosts affect recombinant EPO glycosylation, bioactivity, and consistency, with reproducible N-glycan profiles and absence of α1,3-linked fucosylation.

  5. Characterization Of Fly-Derived Prolactin: Insights Into Glycosylation And Activity 9/26/2026

    Explore how D. mel-derived human prolactin (hPRL) compares with hPRL expressed in E. coli and HEK293 cells through detailed physico-chemical and biological characterization.

  6. Rational Design And Material-sparing Strategies For Enabled Intermediates And Drug Products 9/9/2026

    A material-sparing strategy integrating formulation mapping, lab-scale spray drying, and compact screening can accelerate risk identification and inform first-round tablet formulation decisions for poorly soluble APIs.

  7. Navigating The Development Of Dry Powder For Inhalation 9/9/2026

    A CDMO-authored framework for navigating dry powder inhaler development, covering target product profile definition, API characterization, particle engineering technology selection, and encapsulation considerations.

  8. Overcoming The Obstacles Of Spray-Dried Dispersion Scale-Up 9/9/2026

    SDD scale-up introduces scale-dependent risks that threaten bioavailability, stability, and manufacturability. This white paper details a model-based framework for managing those risks from early feasibility through commercial production.

  9. Enzymatic Strategies For Clinical Development Of Antibody-Drug Conjugate 9/3/2026

    Despite more than 125 ADCs entering clinical trials, only four have reached approval. This review examines why enzymatic conjugation strategies may change that trajectory.

  10. Chemoenzymatic N-glycan Conjugation Of Native mAbs Provides Homogeneous, Efficacious ADCs 9/3/2026

    A chemoenzymatic two-stage protocol enables DAR2 ADCs from native, non-engineered mAbs via glycan remodeling at Asn-297 and copper-free click chemistry, with in vivo efficacy outperforming a comparable marketed ADC.